Bamco Inc. NY Makes New $20.77 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• Bamco Inc. NY purchased 229,603 shares of Edwards Lifesciences in the second quarter, establishing a position worth approximately $20.77 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly EPS of $0.78, beating estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $100.27, compared with the stock’s reported price of $89.97.

Bamco Inc. NY purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 229,603 shares of the medical research company's stock, valued at approximately $20,770,000.

Several other large investors have also added to or reduced their stakes in EW. Bank of America Corp DE acquired a new position in Edwards Lifesciences in the 2nd quarter worth approximately $605,397,000. Magnolia Capital Advisors LLC acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $844,000. Freestone Grove Partners LP acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $15,476,000. Caisse de depot et placement du Quebec acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $87,523,000. Finally, Man Group plc purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $84,597,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,857 shares of company stock worth $170,305. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $89.97 on Friday. The company has a fifty day simple moving average of $89.48 and a two-hundred day simple moving average of $84.99. The company has a market cap of $51.81 billion, a price-to-earnings ratio of 51.71, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the company posted $0.67 earnings per share. The business's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Piper Sandler reissued an "overweight" rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 target price for the company. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Finally, BTIG Research boosted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source